Showing results (251-260 of 299) with videos related to
Sort By:
Pageof 30
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 12, 2005
Risk factors for venous thromboembolic events in cancer patientsK Kröger, D Weiland, C Ose, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1991
Results of the first ESMO examination in medical oncology, London 1989P Alberto, B Mermillod, P G Cocconi, et al.Oncology|August 26, 1999
Induction chemotherapy followed by concurrent chemotherapy and high-dose radiotherapy for locally advanced squamous cell carcinoma of the cervical oesophagusM Stuschke, M Stahl, H Wilke, et al.Journal of the National Cancer Institute|September 24, 1999
Novel tumor suppressor locus in human chromosome region 3p14.2K Jülicher, G Marquitan, N Werner, et al.Blood|November 1, 1991
Minimal residual disease in patients with chronic myelogenous leukemia undergoing long-term treatment with recombinant interferon alpha-2b alone or in combination with interferon gammaB Opalka, U B Wandl, R Becher, et al.British Journal of Urology|April 1, 1996
Genetic instability of 3p12-p21-specific microsatellite sequences in renal cell carcinomaC P Willers, R Siebert, W Bardenheuer, et al.Archiv Der Pharmazie|March 1, 1990
Tumor inhibiting [1,2-bis(fluorophenyl)ethylenediamine]platinum(II) complexes. Part II: Biological evaluation-in vitro studies on the P 388 D1 leukemia cell lineH Reile, R Müller, R Gust, et al.Human Genetics|July 1, 1997
Identification of novel 'expressed sequence tags' within the FHIT gene locus in human chromosome region 3p14.2A Lux, W Bardenheuer, D Michael, et al.Journal of Cancer Research and Clinical Oncology|January 1, 1984
The tumor-inhibiting effect of isomeric dichloro(diphenylethylenediamine)platinum(II) complexesB Wappes, M Jennerwein, E von Angerer, et al.European Journal of Haematology|February 1, 1992
A prospective randomized comparison of single-agent interferon (IFN)-alpha with the combination of IFN-alpha and low-dose IFN-gamma in chronic myelogenous leukaemiaO Kloke, U Wandl, B Opalka, et al.Pageof 30